Stay up to date on the latest oncology and nursing conferences.
Q&A: Nursing Considerations From Immune Cell Effector Therapy Experts
2025 ICE-T Conference presenters explain what nurses and APPs should take into account as immune cell effector therapies become more widely used.
Proactive Rash Management Vital for PI3K, AKT Inhibition in Breast Cancer
Hope S. Rugo, MD, FASCO, emphasized the importance of educating patients about proactive rash and diarrhea management while taking PI3K/AKT inhibitors.
Understanding How On-Target and Off-Target ADC Toxicities Work
Paolo Tarantino, MD, PhD, explains that the chemotherapy-related toxicities from an ADC are more likely to limit dosage for patients with cancer.
Monitoring for Infection-Like AEs Is Essential for CIML NK in GI Cancers
While CIML natural killer immunotherapy can result in infection-like reactions, required prior chemo may cause infections, shared Wenxin (Vincent) Xu, MD.
Belzutifan May Lengthen Quality-Adjusted Survival in Advanced RCC
A quality-adjusted time without symptoms or toxicity analysis identified better outcomes for patients with RCC treated with belzutifan vs everolimus.
KIM-1 Biomarker May Be Prognostic of Response, Outcomes in RCC
Levels of kidney injuring molecule–1 appear to be predictive of therapeutic benefit in patients with renal cell carcinoma.
Neoantigen Vaccine Shows Promise in Mutated Renal Cell Carcinoma
A personalized neoantigen vaccine may be effective in patients with clear cell renal cell carcinoma, shared David A. Braun, MD, PhD.
ADCs Are “Legos,” Customize Cancer Treatment By Target, Safety
Each component of an antibody-drug conjugates—payload, linker, and antibody—play a unique role in building the treatment’s use and safety profile.
Capivasertib Break May Be Needed in Patients With Breast Cancer Experiencing Hyperglycemia
If patients with breast cancer have hyperglycemia or symptoms of it at home, a short break from capivasertib may be required, according to Hope Rugo, MD.
Safety Profiles to Look Out for in New Breast Cancer Treatments
New therapies in breast cancer, particularly ADCs, present unique safety profiles for nurses to be aware of, according to Erika Hamilton, MD.
Real-World Data Tie Early Breast Cancer ctDNA to Recurrence, Lower OS
Data from a research database link ctDNA positivity in early breast cancer with poorer survival and higher recurrence risk.
Allogenic CAR T-Cell Agent Safe, Active in Heavily Pretreated RCC
ALLO-316 showed significant activity and safety in patients with metastatic CD70-positive clear cell renal cell carcinoma.
No Survival, Recurrence Benefit With Aspirin in CRC Liver Metastases
Adjuvant aspirin did not reduce recurrence or improve survival in patients with CRC liver metastases, phase 3 data showed at the 2025 ASCO Meeting.
Relacorilant Combo Sustains Ovarian Cancer Benefit Post Platinum Break
The combination of relacorilant and nab-paclitaxel improved survival in platinum-resistant ovarian cancer following a break from platinum-based chemo.
Genomic Changes May Drive Sotorasib KRAS G12C+ Combo Resistance in CRC
Biomarker data from CodeBreaK 300 suggest DNA and RTK pathway alterations may underlie resistance to sotorasib plus panitumumab in CRC.
Relacorilant/Nab-Paclitaxel Is Convenient, Safe in Ovarian Cancer
In addition to a significant PFS benefit vs nab-paclitaxel alone, the combination provides an at-home option for patients with ovarian cancer.
Neoadjuvant Nivolumab Regimen Improves OS in Resectable NSCLC
Nivolumab plus chemotherapy significantly improved OS vs chemo alone in resectable NSCLC, per updated CheckMate-816 findings.
Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer
Relacorilant plus nab-paclitaxel improved PFS and showed a trend toward longer OS in platinum-resistant ovarian cancer in ROSELLA.
Nivolumab/Ipilimumab to Be New MSI-H/dMMR mCRC Standard of Care
Lasting survival benefits vs chemotherapy or monotherapy were achieved with nivolumab and ipilimumab for patients with MSI-H/ dMMR metastatic colorectal cancer.
T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations
T-DXd led to an ORR of 59.4% vs 33.9% with chemo, regardless of biomarker status, in HR+, HER2-low metastatic breast cancer, per DESTINY-Breast06.
AI Tool May Predict Response, Resistance in Advanced RCC
A machine learning model applied to CheckMate 9ER may help predict outcomes and resistance in advanced renal cell carcinoma.
Olanzapine May Reduce Nausea, Vomiting From Radiation
Olanzapine plus an antiemetic shows potential in preventing RINV while reducing other adverse events such as depression, appetite loss, and insomnia.
Pembrolizumab Plus CCRT Could Become SOC in High-Risk Cervical Cancer
Final KEYNOTE-A18 results show sustained survival benefit with pembrolizumab plus concurrent chemoradiation in locally advanced cervical cancer.
Zilovertamab Vedotin Plus R-GemOx Shows Activity in R/R DLBCL
The ROR1-targeted ADC plus R-GemOx led to a 56.3% ORR in patients with relapsed or refractory diffuse large B-cell lymphoma in waveLINE-003.
Luspatercept Improves Transfusion Independence in Lower-Risk MDS
Luspatercept led to durable red blood cell transfusion independence and early OS signals in ESA-naive, lower-risk MDS, per updated COMMANDS data.
Nurses, APPs Can Help Prevent Parkinsonism During Cilta-Cel in Myeloma
By monitoring patients’ CBC and other symptoms, nurses and advanced practice providers can spot early indicators of parkinsonism risk, per Yi Lin, MD, PhD.
Chemo With Molecular Guidance Improves Survival in Early NSCLC
A molecular assay identified patients with non–small cell lung cancer most likely to benefit from adjuvant chemotherapy, leading to prolonged survival.
Tarlatamab Supported as Second-Line SOC by DeLLphi-304 in SCLC
Tarlatamab prolonged both overall and progression-free survival in the treatment of small cell lung cancer, backing it as a second-line standard of care.
First-Line T-DXd/Pertuzumab Yields Improved PFS in HER2+ mBC
The combination of trastuzumab deruxtecan with pertuzumab shows promise as a standard of care for HER2-positive advanced breast cancer.
Dermatologic Protocol Preserves QOL in EGFR+ Advanced NSCLC Treatment
COCOON skin care led to fewer or milder dermatologic symptoms with amivantamab/lazertinib vs standard care in patients with EGFR+ advanced NSCLC.